ArticleThe Journal of infectious diseases2011
Evaluation of therapeutic interventions for vaccinia virus keratitis.
Article in The Journal of infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- A systematic review to identify novel clinical characteristics of monkeypox virus infection and therapeutic and preventive strategies to combat the virus.Archives of virology · 2023Pooled it
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- Mpox unveiled: Global epidemiology, treatment advances, and prevention strategies.One health (Amsterdam, Netherlands) · 2025Review
- "Mpox in MSM: Tackling stigma, minimizing risk factors, exploring pathogenesis, and treatment approaches".Biomedical journal · 2025Review
- Mpox Virus and its ocular surface manifestations.The ocular surface · 2024Review
- Managing Monkeypox Virus Infections: A Contemporary Review.Iranian journal of medical sciences · 2024Review
- Spectrum of ophthalmic manifestations in monkeypox virus infection worldwide: Systematic review and meta-analysis.Heliyon · 2023Review
- Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts.bioRxiv : the preprint server for biology · 2023Article
- Interim Clinical Treatment Considerations for Severe Manifestations of Mpox - United States, February 2023.MMWR. Morbidity and mortality weekly report · 2023Article
- A Review of Monkeypox Ocular Manifestations and Complications: Insights for the 2022 Outbreak.Ophthalmology and therapy · 2023Review
- Ocular MPox: A report of two cases.IDCases · 2023Article
- Monkeypox: A clinical update for paediatricians.Journal of paediatrics and child health · 2022Review
- Safety and efficacy of tacrolimus-coated silicone plates as an alternative to mitomycin C in a rabbit model of conjunctival fibrosis.PloS one · 2019Article
- Review
- Both CD8+ and CD4+ T Cells Contribute to Corneal Clouding and Viral Clearance following Vaccinia Virus Infection in C57BL/6 Mice.Journal of virology · 2016Article
- Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.Antiviral research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundVaccinia virus keratitis (VACVK) is a complication of smallpox vaccination that can result in blindness. There are no Food and Drug Administration-approved treatments for VACVK, and vaccinia immunoglobulin (VIG) is contraindicated in isolated VACVK. We used a rabbit model of infection to compare several therapeutic options for VACVK.
methodsRabbit eyes were infected with 10(5) plaque-forming units of the Dryvax strain of vaccinia virus and scored daily for 28 days using a modified MacDonald-Shadduck scoring system. Animals were treated for 10 days after the onset of keratitis with albumin, VIG, prednisolone acetate, trifluridine, or combinations thereof. Ocular viral titers and vaccinia-specific antibody titers were determined by plaque assay and enzyme-linked immunosorbent assay, respectively.
resultsTreatment with intravenous VIG neither exacerbated nor ameliorated VACVK. Topical prednisolone acetate interfered with viral clearance, and ocular disease rebounded in prednisolone-treated groups. The most effective treatment was topical trifluridine alone.
conclusionsWe conclude that (1) VIG did not negatively affect the treatment of isolated keratitis, (2) topical corticosteroids should not be used for treating VACVK, and (3) treatment with topical trifluridine, with or without intravenous VIG, is the preferred therapeutic regimen for treating VACVK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.